Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery
Abstract
Background Current guidelines do not offer detailed recommendations on antidiabetic drug therapy in type 2 diabetes (T2D) after bariatric surgery (BS), and reported experience is scarce.Objectives To evaluate the effectiveness and tolerability of liraglutide at 2 years in patients with morbid obesity after undergoing BS and subsequent relapse, persistence, or new diagnosis of T2D, comparing the results with a cohort of nonsurgical diabetic patients also treated with liraglutide.Setting Obesity clinic at a University Hospital.Methods We conducted a retrospective study of 2 cohorts of patients (with and without previous BS) with T2D and obesity who had started treatment with liraglutide at least 2 years before their inclusion in the study. The main outcome measures were the differences in glycated hemoglobin (A1C) and weight at 104 weeks between both groups.Results A total of 164 patients were included, 15 with previous BS and 149 without BS. Mean baseline parameters were A1C 6.6% and body mass index 40.3 kg/m 2 for the BS group, and A1C 7.5% and body mass index 39.7 kg/m 2 for the non-BS group. At 2 years, A1C and weight were significantly decreased in both groups (BS group: ΔA1C -0.39%, Δweight -3.4 kg; non-BS group: ΔA1C -0.67%, Δweight -3.8 kg; all results P<.05), with no significant differences in A1C and weight reduction between both groups. There was a significant lower frequency of withdrawals due to all causes and a nonsignificant lower rate of vomiting and hypoglycemia in patients with BS.Conclusions Liraglutide achieved a significant reduction in weight and A1C at 2 years in patients with T2D previously treated with BS, showing good gastrointestinal tolerance.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The role of GLP1-RAs in treating weight regain after bariatric surgery is still not defined.
“Their role in the treatment of weight regain after bariatric surgery remains to be defined.”
Most reports on GLP1-RA efficacy in patients with weight regain after bariatric surgery are limited to liraglutide and come from observational studies or case reports.
“Reports on the efficacy of GLP1-RAs in patients with weight regain after bariatric surgery are mostly limited to liraglutide in observational studies or case reports [9–20].”
Cites
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457 · see citing works
Mechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M. M., Heinberg, L. J., Kushner, R., Adams, T. D., Shikora, S., et al. (2013) · Obesity · doi:10.1002/oby.20461 · Cited by 1,650 · see citing works
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · see citing works
Sjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, Å., Bouchard, C., Carlsson, B., Karason, K., Lönroth, H., et al. (2014) · JAMA · doi:10.1001/jama.2014.5988 · Cited by 1,054 · see citing works
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · see citing works
Heber, D., Greenway, F. L., Kaplan, L. M., Livingston, E., Salvador, J., & Still, C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2128 · Cited by 521 · see citing works
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works
Ribaric, G., Buchwald, J. N., & McGlennon, T. W. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1160-3 · Cited by 267 · see citing works
Bariatric and metabolic surgery: a shift in eligibility and success criteria
Frühbeck, G. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.84 · Cited by 230 · see citing works
Panunzi, S., Gaetano, A. D., Carnicelli, A., & Mingrone, G. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000863 · Cited by 187 · see citing works
Liraglutide and obesity: a review of the data so far
Ladenheim, E. E. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 147 · see citing works
Zinman, B., Schmidt, W. E., Moses, A. C., Lund, N., & Gough, S. C. L. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01493.x · Cited by 119 · see citing works
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97 · see citing works
Tratamento de curto prazo com liraglutide no reganho de peso após cirurgia bariátrica
Pajecki, D., Halpern, A., Cercato, C., Mancini, M., Cleva, R. D., & Santo, M. A. (2013) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/s0100-69912013000300005 · Cited by 93 · see citing works
Medical management of patients after bariatric surgery: Principles and guidelines
Elrazek, A. E. A., Elbanna, A., & Bilasy, S. E. (2014) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v6.i11.220 · Cited by 88 · see citing works
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Miras, A. D., & le Roux, C. W. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.205 · Cited by 63 · see citing works
Zavattaro, M., Caputo, M., Samà, M. T., Mele, C., Chasseur, L., Marzullo, P., Pagano, L., Mauri, M. G., Ponziani, M. C., Aimaretti, G., et al. (2015) · Endocrine · doi:10.1007/s12020-014-0519-0 · Cited by 57 · see citing works
Treatment of Diabetes Prior to and after Bariatric Surgery
Thorell, A., & Toft, E. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600528 · Cited by 41 · see citing works
Metabolic bariatric surgery and type 2 diabetes mellitus: an endocrinologist’ s perspective
Sonali, G., Hong, C., Phong, C., & Tham, K. W. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.29.20140127 · Cited by 24 · see citing works
GLP-1R Agonism Enhances Adjustable Gastric Banding in Diet-Induced Obese Rats
Habegger, K. M., Kirchner, H., Yi, C., Heppner, K. M., Sweeney, D. C., Ottaway, N., Holland, J., Amburgy, S. E., Raver, C., Krishna, R., et al. (2013) · Diabetes · doi:10.2337/db13-0117 · Cited by 21 · see citing works
Metabolic surgery for type 2 diabetes
Halperin, F., & Goldfine, A. B. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835edbb0 · Cited by 19 · see citing works
Metabolic surgery: A paradigm shift in type 2 diabetes management
Pappachan, J. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.990 · Cited by 17 · see citing works
Rothkopf, M. M., Bilof, M. L., Haverstick, L. P., & Nusbaum, M. J. (2009) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2008.09.005 · Cited by 15 · see citing works
Metabolic bariatric surgery and type 2 diabetes mellitus：an endocrinologist’s perspective
Sonali, S., Ganguly, Hồng, Chang, Tan, �., Phong, Ching, Lee, Kwang, Wei, et al. (2015) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 12 · see citing works
Liraglutide—another weapon in the war against obesity?
Bray, G. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.133 · Cited by 10 · see citing works
An update on the role of bariatric surgery in diabetes management
Malkani, S. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000143 · Cited by 10 · see citing works
Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?
Raffaelli, M., Sessa, L., Mingrone, G., & Bellantone, R. D. A. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s50659 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Miras, A. D., Pérez-Pevida, B., Aldhwayan, M., Kamocka, A., McGlone, E. R., Al-Najim, W., Chahal, H., Batterham, R. L., McGowan, B., Khan, O., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30157-3 · Cited by 190 · see citing works
Obesity in South and Southeast Asia—A new consensus on care and management
Tham, K. W., Abdul Ghani, R., Cua, S. C., Deerochanawong, C., Fojas, M., Hocking, S., Lee, J., Nam, T. Q., Pathan, F., Saboo, B., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13520 · Cited by 187 · see citing works
“Of the available antiobesity medications, the best studied in the postbariatric setting is liraglutide, which appears to be similarly well tolerated and efficacious in bariatric patients as in others with obesity.(206,232) Liraglutide is particularly useful in patients requiring better diabetes control after bariatric…”
BackgroundJensen, A. B., Renström, F., Aczél, S., Folie, P., Biraima-Steinemann, M., Beuschlein, F., & Bilz, S. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06484-8 · Cited by 161 · see citing works
Long-Term Weight Loss Strategies for Obesity
Kheniser, K., Saxon, D. R., & Kashyap, S. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab091 · Cited by 139 · see citing works
“In 1 retrospective study, weight and HbA1c were reduced by 3.4 kgs and 0.39%, respectively (148).”
InfluentialRye, P., Modi, R., Cawsey, S., & Sharma, A. M. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3393-7 · Cited by 97 · see citing works
Kalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 58 · see citing works
Llewellyn, D. C., Logan Ellis, H., Aylwin, S. J. B., Oštarijaš, E., Green, S., Sheridan, W., Chew, N. W. S., le Roux, C. W., Miras, A. D., Patel, A. G., et al. (2023) · Obesity · doi:10.1002/oby.23600 · Cited by 54 · see citing works
“[46] may have under-recorded events because hypoglycemia assessment was”
BackgroundInfluentialDutta, D., Nagendra, L., Joshi, A. S., Krishnasamy, S., Sharma, M., & Parajuli, N. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07175-8 · Cited by 57 · see citing works
Use of weight loss medications in patients after bariatric surgery.
Redmond, I. P., Shukla, A. P., & Aronne, L. J. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00425-1 · Cited by 50 · see citing works
“…comorbidities P=median 35.3 months PT=median 36.3 months 3 months % excess weight loss P=12.8 (95% CI 4.25, 8.44) PT=12.9 (95% CI 1.08, 6.54) Gorgojo-Martinez et al. (2016) Liraglutide 1.2–1.8 mg/day in nonsurgical (NS) and surgical (S) NS=149 S=15 Patients with diabetes prescribed…”
BackgroundInfluentialElhag, W., & El Ansari, W. (2022) · Obesity Surgery · doi:10.1007/s11695-021-05884-y · Cited by 49 · see citing works
Pharmacologic management of weight regain following bariatric surgery.
Lucas, E., Simmons, O., Tchang, B., & Aronne, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043595 · Cited by 41 · see citing works
“Furthermore, there were significantly fewer discontinuations of liraglutide in patients with a history of bariatric surgery compared to those without a history of bariatric surgery (26).”
BackgroundInfluentialEsparham, A., Mehri, A., Dalili, A., Richards, J., & Khorgami, Z. (2024) · Obesity Reviews · doi:10.1111/obr.13811 · Cited by 41 · see citing works
“31 Moreover, Kanai et al. showed that semaglutide at a maximum dose of 1.0 mg weekly for a period of 12 months significantly lowered HbA1c from 6.3% to 5.7%.”
InfluentialReview of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy
Sudlow, A. C., le Roux, C. W., & Pournaras, D. J. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819875407 · Cited by 30 · see citing works
Sudlow, A. C., le Roux, C. W., & Pournaras, D. J. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04206-7 · Cited by 31 · see citing works
Cunningham, J. G., Szoka, N. L., Tabone, L. E., Cox, S. J., Aylward, L., & Abunnaja, S. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.01.021 · Cited by 27 · see citing works
Kramer, C. K., Retnakaran, M., & Viana, L. V. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae176 · Cited by 29 · see citing works
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26 · see citing works
“Liraglutide was also shown to be safe and can induce further weight loss and reductions in A1C in patients with type 2 diabetes who have had bariatric surgery.(179) Higher doses of liraglutide result in a greater proportion of patients reporting symptoms of nausea (48%) and vomiting (13%) and other symptoms, as noted…”
BackgroundAn Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
Enright, C., Thomas, E., & Saxon, D. R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac195 · Cited by 27 · see citing works
Dréant, A., Blanchard, C. L., & Jacobi, D. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07127-2 · Cited by 24 · see citing works
“Several factors may explain this difference, such as data availability in selected studies, dosage adjustments based on patient tolerance, and potentially increased tolerance to digestive side effects in patients who have undergone bariatric surgery, as suggested by Gorgojo et al. [41].”
Rubio, M. Á., Carreiro, S. M., Sánchez-Pernaute, A., & Ramos-Levi, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102785 · Cited by 23 · see citing works
“…In this regard, GLP1 receptor agonists have been one of the most frequently evaluated drugs for weight treat-ment, but data are limited to small retrospective and observational studies with short-term follow-up (less than 6 months), reaching 3.4–9.7% weight loss, depending on the dose used [11–15].”
BackgroundInfluentialWeight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
Imam, A. A., Alim, H., Binhussein, M., Kabli, A. F., Alhasnani, H., Allehyani, A., Aljohani, A. M., Mohorjy, A., Tawakul, A. A., Samannodi, M. S., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad129 · Cited by 21 · see citing works
“Liraglutide’s effect on HbA1c reduction and weight loss was significant among patients with and without BS in Gorgojo-Martínez et al’s study [50].”
BackgroundTan, Y. W., Shang, M., Davis, S., & Gananadha, S. (2025) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-025-03831-4 · Cited by 21 · see citing works
Diabetes management before, during, and after bariatric and metabolic surgery
Kheniser, K. G., & Kashyap, S. R. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.06.006 · Cited by 19 · see citing works
Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US
Kim, M., Schweitzer, M., Kim, J. S., Alexander, G. C., & Mehta, H. B. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3089 · Cited by 17 · see citing works
Schneider, R., Kraljević, M., Peterli, R., Rohm, T. V., Klasen, J. M., Cavelti‐Weder, C., & Delko, T. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04750-7 · Cited by 17 · see citing works
“[41] Retrospective cohort LRYGB (n = 8), BPD (n = 3), VBG (n = 2), LSG (n = 1), AGB (n = 1) Liraglutide 1.”
BackgroundMethodInfluentialKim, K. K. (2019) · Korean Journal of Family Medicine · doi:10.4082/kjfm.19.0013 · Cited by 17 · see citing works
Kashyap, S. R., Kheniser, K. G., Aminian, A., Schauer, P. R., le Roux, C. W., & Burguera, B. G. (2020) · Obesity Science & Practice · doi:10.1002/osp4.409 · Cited by 16 · see citing works
“two years in the liraglutide study), weight loss outcomes paralleled that of liraglutide in a retrospective study that investigated its effects in a similar population [9].”
BackgroundResultGutt, S., Schraier, S., Bagnes, M. F. G., Yu, M., González, C. D., & Girolamo, G. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583746 · Cited by 16 · see citing works
Jamal, M. H., Qasem, W., Hamshari, F., Dsouza, C. L., Alqallaf, N., Otiku, P., & Nnaji, C. A. (2023) · Obesity Science & Practice · doi:10.1002/osp4.706 · Cited by 15 · see citing works
“17,18 T A B L E 2 Patients' mean weights before and after liraglutide treatment and associated mean weight changes.”
BackgroundPharmacological treatment of non-responders following bariatric surgery
Vinciguerra, F., ROMEO, L. M., Frittitta, L., & Baratta, R. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03311-3 · Cited by 15 · see citing works
Mousavi, A., Shojaei, S., Azarboo, A., Bahri, R. A., Mohammadi, S., Alilou, S., Yousefifar, S., Maleki, S., & Radkhah, H. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01770-z · Cited by 13 · see citing works
Wharton, S., Kamran, E., Muqeem, M., Khan, A., & Christensen, R. A. G. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1678478 · Cited by 13 · see citing works
Xie, J., & Wang, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001320 · Cited by 10 · see citing works
“This observation might be connected to postoperative alterations in hormone levels and gastrointestinal anatomy [61] .”
BackgroundAdjuvant and Neo-Adjuvant Anti-Obesity Medications and Bariatric Surgery: A Scoping Review
Sher, T., McGee, M. Y., DuCoin, C. G., Sujka, J. A., & Docimo, S. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00558-z · Cited by 10 · see citing works
“In a study by Gorgojo-Martínez et al. (2016), adjuvant use of liraglutide 1.2–1.8 mg daily after a median of 5.2 years following bariatric surgery (RYGB, biliopancreatic diversion, gastroplasty, AGB, or SG) was compared with liraglutide use without bariatric surgery [43].”
InfluentialLupoli, R., Lembo, E., Giosuè, A., Schiavo, L., & Capaldo, B. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.02.019 · Cited by 9 · see citing works
Golzarand, M., Toolabi, K., & Mirmiran, P. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01807-4 · Cited by 6 · see citing works
“Sixteen studies ( n = 873) reported the effects of liraglutide prescription on weight, BMI, or %TWL [29, 34 – 36, 39, 41, 43, 44, 48 – 54, 56], six studies ( n = 240) assessed the effects of semaglutide [33, 42, 44, 46, 47, 51], and one study ( n = 45) determined the effects of tirzepatide [42].”
InfluentialJordan, G., Young, S., & Alemán, J. O. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.006 · Cited by 6 · see citing works
Arrowaili, A. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07856-y · Cited by 5 · see citing works
Evaluating the use of adjuvant and neoadjuvant terminology in bariatric surgery: a scoping review
Sher, T., McGee, M. Y., DuCoin, C. G., Sujka, J. A., & Docimo, S. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.03.009 · Cited by 6 · see citing works
Kheniser, K. G., Aminian, A., & Kashyap, S. R. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01350-8 · Cited by 5 · see citing works
Treating T2DM and obesity with bariatric surgery and GLP1 agents
Bailey, C. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0240-4 · Cited by 2 · see citing works
Paired Editorial: How should residual or recurrent diabetes after bariatric surgery be managed?
Monteiro, M. P. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.03.019 · Cited by 2 · see citing works
de Waal, J. R., Nieuwdorp, M., & Gerdes, V. E. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1680182 · Cited by 1 · see citing works
Pi, Y., Du, T. T., & Zhao, P. (2022) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.976 · Cited by 1 · see citing works
“The major outcomes of the follow-up survey were the changes in body weight, combined BMI and glycosylated hemoglobin.”
BackgroundInfluentialMazaheri, T., Ansari, S., Nallagonda, M., Kollmann, L., Nickel, F., Seyfried, F., & Miras, A. D. (2023) · Die Chirurgie · doi:10.1007/s00104-023-01830-z · Cited by 1 · see citing works
Chiappetta, S., & Stier, C. K. (2022) · Springer eBooks · doi:10.1007/978-3-662-63705-0_17 · Cited by 1 · see citing works
Alves, M., Pedrosa, C. A., Freitas, C., Rocha, G., Albuquerque, I., Duarte, J., Cardoso, L., Carvalho, R., Belo, S., Azevedo, T., et al. (2019) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/na190001 · Cited by 1 · see citing works
Poor responders after bariatric surgery – Are there second chances?
Pérez‐Pevida, B., & Kamocka, A. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.11.002
“Therefore, GLP-1analogues have a potential to enhance surgical outcomes as shown in several retrospective observational studies.(8,9) Another line of treatment can be provided by a relatively new group of glucose-lowering medications, sodium--glucose cotransporter-2 (SGLT2) inhibitors.”
BackgroundMultimodal Care for Diabetes Combining Pharmacotherapy and Metabolic Surgery
Ansari, S., & Miras, A. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-54064-7_102-1
(2017) · Reactions Weekly · doi:10.1007/s40278-017-29162-7
Poor responders after bariatric surgery – Are there second chances?
Pérez‐Pevida, B., & Kamocka, A. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.02.001
Multimodal Care for Diabetes Combining Pharmacotherapy and Metabolic Surgery
Ansari, S., & Miras, A. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-60596-4_102
Traitement pharmacologique du diabète de type 2 après chirurgie bariatrique/métabolique
Scheen, A. J. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.05.006
Chiappetta, S., & Stier, C. K. (2023) · Springer eBooks · doi:10.1007/978-3-662-66436-0_17
Role of Incretin Mimetics in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_4
Corum, S., Morgan, T., & Thomas, A. M. (2025) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2025.100020
Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies
Sridharan, K., & Sivaramakrishnan, G. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01988-y · Cited by 1 · see citing works
GLP-1 Receptor Agonists in Recurrent Weight Gain after Metabolic Bariatric Surgery
Manyari, Á. A. O., & Manyari, A. L. A. A. A. J. D. O. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016875
Fujishiro, M., Hagiwara, K., Nemoto, A., Kuroyanagi, H., Nosoko, M., Okamura, N., Kon, U., Uchida, H., Ogawa, K., & Ishihara, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1895420
“They have also been reported as effective for weight regain in patients with or without T2DM after MBS (17 – 20).”
InfluentialMonteiro, M. P., Frutuoso, J. F., Pereira, S. S., Guimarães, M., & Monteiro, M. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870008
- Authors
- Gorgojo-Martínez, J. J., Feo-Ortega, G., & Serrano-Moreno, C.
- Affiliations
- Hospital Universitario Fundación Alcorcón (ES)
- Venue
- Surgery for Obesity and Related Diseases
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 12
- Issue
- 10
- Pages
- 1856-1863
- ISSN
- 1550-7289 (ISSN-L)
- OpenAlex
- W2284097691
- Cited by
- 60
- References
- 27
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 8 · 2023: 11 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 9 · 2018: 3 · 2017: 3 · 2016: 1
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Surgery for Obesity and Related Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, type 2 diabetes
- MeSH terms
- Liraglutide, Aged, Analysis of Variance, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Morbid, Retrospective Studies, Body Mass Index, Treatment Outcome, Bariatric Surgery, Drug Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
